Use of thiopurines in inflammatory bowel disease

被引:1
|
作者
Pascal Frei [1 ]
Luc Biedermann [1 ]
Ole Haagen Nielsen [2 ]
Gerhard Rogler [1 ]
机构
[1] Division of Gastroenterology and Hepatology,Department of Internal Medicine,University Hospital of Zürich,CH-8091 Zürich,Switzerland
[2] Department of Gastroenterology,Medical Section,Herlev Hospital,University of Copenhagen,DK-2730 Herlev,Denmark
关键词
Thiopurines; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Immunosuppression; Infection;
D O I
暂无
中图分类号
R574 [肠疾病];
学科分类号
1002 ; 100201 ;
摘要
The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn’s disease and ulcerative colitis.Nevertheless,many questions remain concerning the optimal treatment regimens of azathioprine,6-mercaptopurine and thioguanine.We will briefly summarize dose recommendations,indications for thiopurine therapy and side effects which are relevant in clinical practice.We discuss some currently debated topics,including the combination of azathioprine and allopurinol,switching of thiopurine therapy in case of side effects,the use of azathioprine in pregnancy,the infection risk using thiopurines and the evidence when to stop thiopurines.Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail.
引用
收藏
页码:1040 / 1048
页数:9
相关论文
共 50 条
  • [1] Use of thiopurines in inflammatory bowel disease
    Frei, Pascal
    Biedermann, Luc
    Nielsen, Ole Haagen
    Rogler, Gerhard
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (07) : 1040 - 1048
  • [2] Optimising use of thiopurines in inflammatory bowel disease
    Raj, Lawrence Sunder
    Hawthorne, A. Barney
    FRONTLINE GASTROENTEROLOGY, 2010, 1 (01) : 44 - 51
  • [3] Optimizing the use of thiopurines in inflammatory bowel disease
    Goel, Rishi M.
    Blaker, Paul
    Mentzer, Alex
    Fong, Steven C. M.
    Marinaki, Anthony M.
    Sanderson, Jeremy D.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (03) : 138 - 146
  • [4] Use of thiopurines in inflammatory bowel disease: an update
    Singh, Arshdeep
    Mahajan, Ramit
    Kedia, Saurabh
    Dutta, Amit Kumar
    Anand, Abhinav
    Bernstein, Charles N.
    Desai, Devendra
    Pai, C. Ganesh
    Makharia, Govind
    Tevethia, Harsh Vardhan
    Mak, Joyce W. Y.
    Kaur, Kirandeep
    Peddi, Kiran
    Ranjan, Mukesh Kumar
    Arkkila, Perttu
    Kochhar, Rakesh
    Banerjee, Rupa
    Sinha, Saroj Kant
    Ng, Siew Chien
    Hanauer, Stephen
    Verma, Suhang
    Dutta, Usha
    Midha, Vandana
    Mehta, Varun
    Ahuja, Vineet
    Sood, Ajit
    INTESTINAL RESEARCH, 2022, 20 (01) : 11 - 30
  • [5] Optimising use of thiopurines in inflammatory bowel disease
    Dart, Robin J.
    Irving, Peter M.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (09) : 877 - 888
  • [6] Use of thiopurines in inflammatory bowel disease: Safety issues
    Anastasia Konidari
    Wael El Matary
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, (02) : 63 - 76
  • [7] Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease
    Johnson C.M.
    Dassopoulos T.
    Current Gastroenterology Reports, 2018, 20 (11)
  • [8] TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease
    Stocco, G
    Martelossi, S
    Barabino, A
    Fontana, M
    Lionetti, P
    Decorti, G
    Malusà, N
    Bartoli, F
    Fezzi, M
    Giraldi, T
    Ventura, A
    DIGESTIVE AND LIVER DISEASE, 2005, 37 (12) : 940 - 945
  • [9] Thiopurines in inflammatory bowel disease revisited
    Baer, Florian
    Sina, Christian
    Fellermann, Klaus
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (11) : 1699 - 1706
  • [10] Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
    Derijks, L. J. J.
    Wong, D. R.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (02) : 145 - 154